GENB · Company research
Generate Biomedicines, Inc. (GENB): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Fund Update: New $26.6M $GENB stock position opened by BANQUE PICTET & CIE SA - Quiver Quantitative | Fund Update: New $26.6M $GENB stock position opened by BANQUE PICTET & CIE SA Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 16, 2026 | neutral | 0 | 0.6 |
| Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition | The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR. India's pharmaceutical market recorded 17.1% year-over-year growth in September 2026. Key growth drivers include biologics, AI-driven drug discovery, specialty medicines, and manufacturing investments. Asia Pacific is expected to grow faster than the global average at 7.02% CAGR, while North America maintains 36% market share. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition | The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR. India's pharmaceutical market recorded 17.1% year-over-year growth in September 2026. Key growth drivers include biologics, AI-driven drug discovery, specialty medicines, and manufacturing investments. Asia Pacific is expected to grow faster than the global average at 7.02% CAGR, while North America maintains 36% market share. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| Generate Biomedicines, Inc. (GENB) stock price, news, quote and history - Yahoo Finance UK | Generate Biomedicines, Inc. (GENB) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 15, 2026 | neutral | 0 | 0.6 |
| Up to nearly $1.2B in milestones is tied to Generate's planned AI research on obesity drugs. - Stock Titan | Up to nearly $1.2B in milestones is tied to Generate's planned AI research on obesity drugs. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm (NASDAQ:GENB) - Seeking Alpha | Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm (NASDAQ:GENB) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat | Top Generate Biomedicines (GENB) Competitors 2026 MarketBeat | View source ↗ | MarketBeat | Oct 11, 2026 | neutral | 0 | 0.6 |
| Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - Timothy Sykes | Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ Timothy Sykes | View source ↗ | Timothy Sykes | Oct 10, 2026 | neutral | 0 | 0.6 |
| NVIDIA CORP's Generate Biomedicines Inc(GENB) Holding History - GuruFocus | NVIDIA CORP's Generate Biomedicines Inc(GENB) Holding History GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Generate Biomedicines Inc (GENB-Q) Stock Price and News - The Globe and Mail | Generate Biomedicines Inc (GENB-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 6, 2026 | neutral | 0 | 0.6 |
| Generate Biomedicines (NasdaqGS:GENB) Stock Forecast & Analyst Predictions - Simply Wall Street | Generate Biomedicines (NasdaqGS:GENB) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| An ovarian cancer trial tests cell therapy without chemotherapy beforehand. Its first patient has been dosed. - Stock Titan | An ovarian cancer trial tests cell therapy without chemotherapy beforehand. Its first patient has been dosed. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Generate Biomedicines (NasdaqGS:GENB) Stock Price - Simply Wall Street | Generate Biomedicines (NasdaqGS:GENB) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Sep 21, 2026 | neutral | 0 | 0.6 |
| Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns - Yahoo Finance | Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns Yahoo Finance | View source ↗ | Yahoo Finance | Aug 26, 2026 | neutral | 0 | 0.6 |
| Generate Biomedicines surges again, rises 12% to new high (GENB:NASDAQ) - Seeking Alpha | Generate Biomedicines surges again, rises 12% to new high (GENB:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 25, 2026 | neutral | 0 | 0.6 |
| Market Movers | Winners: CYPH, FWDI, GENB | Losers: RGNX, AIAI, TMS - Trefis | Market Movers | Winners: CYPH, FWDI, GENB | Losers: RGNX, AIAI, TMS Trefis | View source ↗ | Trefis | Aug 25, 2026 | neutral | 0 | 0.6 |
| GENB Stock Price and Chart — NASDAQ:GENB - TradingView | GENB Stock Price and Chart — NASDAQ:GENB TradingView | View source ↗ | TradingView | Aug 25, 2026 | neutral | 0 | 0.6 |
| $GENB stock is up 14% today. Here's what we see in our data. - Quiver Quantitative | $GENB stock is up 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 4, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Feb 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.